Do preoperative serum vascular endothelial growth factor and migration-inhibitory factor predict the nature of the adnexal masses? A prospective-controlled trial

References

• Agarwal R, Whang DH, Alvero AB, Visintin I, Lai Y, Segal EA, et al. 2007. Macrophage migration inhibitory factor expression in ovarian cancer. American Journal of Obstetrics and Gynecology 196:348.e1–348.e5.
   PubMedGoogle Scholar
• Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. 2003. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circulation Research 93:321–329
   PubMed Web of Science ®Google Scholar
• Bacher M, Eickmann M, Schrader J, Gemsa D, Heiske A. 2002. Human cytomegalovirus-mediated induction of MIF in fibroblasts. Virology 299:32–37
   PubMed Web of Science ®Google Scholar
• Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G, et al. 2003. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. American Journal of Pathology 162:11–17.
   PubMed Web of Science ®Google Scholar
• Bloom BR, Bennett B. 1966. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80–82
   PubMed Web of Science ®Google Scholar
• Bristow RE, Palis BE, Chi DS, Cliby WA. 2010. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecologic Oncology 118:262–267.
   PubMed Web of Science ®Google Scholar
• Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. 2005. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. American Journal of Obstetrics and Gynecology 193:1630–1639.
   PubMed Web of Science ®Google Scholar
• Chen C, Cheng W, Lee C, Chen T, Kung CS, Hsieh F, et al. 1999. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecologic Oncology 74:235–240.
   PubMed Web of Science ®Google Scholar
• Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. 1999. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Molecular Medicine 5:181–191.
   PubMed Web of Science ®Google Scholar
• Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. 2001. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology 82:532–537.
   PubMed Web of Science ®Google Scholar
• Donn RP, Ray DW. 2004. Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. Journal of Endocrinology 182:1–9.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP. 2003. The biology of VEGF and its receptors. Nature Medicine 9:669–676.
   PubMed Web of Science ®Google Scholar
• Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R, et al. 2003. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proceedings of the National Academy of Sciences of the United States of America 100:9354–9359.
   PubMed Web of Science ®Google Scholar
• Folkamn J. 1971. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285:1182–1186.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Ferdeghini M, Fanucchi A, Annicchiarico C, Ciampi B, Prontera B, et al. 1999. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variable and clinical outcome. Anticancer Research 19:1401–1406.
   PubMed Web of Science ®Google Scholar
• Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR. 2007. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Molecular Cancer Therapeutics 6:1993–2002.
   PubMed Web of Science ®Google Scholar
• Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A, et al. 2005. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 103:588–598.
   PubMed Web of Science ®Google Scholar
• Hsich CY, Chen CA, Chov CH. 2004. Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis. Journal of Biomedical Science 11:249–259.
   PubMed Web of Science ®Google Scholar
• Hu L, Hofman J, Jaffle RB. 2005. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clinical Cancer Research 11:8208–8212.
   PubMed Web of Science ®Google Scholar
• Hu YL, Tee MK, Goetzl EJ. 2001. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. Journal of the National Cancer Institute 93:763–768.
   Google Scholar
• Kraft A, Weindel K, Ochs A. 1999. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178–187.
   PubMed Web of Science ®Google Scholar
• Krockenberger M, Kranke P, Häusler S, Engel JB, Horn E, Nürnberger K, et al. 2012. Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis. Anticancer Research 32:5233–5238.
   PubMed Web of Science ®Google Scholar
• Legendre H, Decaestecker C, Nagy N, Hendlisz A, Schüring MP, Salmon I, et al. 2003. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Modern Pathology 16:491–504.
   PubMed Web of Science ®Google Scholar
• Lin W, Chen S, Li M, Wang B, Qu X, Zhang Y. 2010. Expression of macrophage migration inhibitory factor in human endometriosis: relation to disease stage, menstrual cycle and infertility. Journal of Obstetrics and Gynaecology Research 36:344–351.
   PubMed Web of Science ®Google Scholar
• Lutz AM, William JK, Drescher CW, Ray P, Cochron FV, Urban N, et al. 2011. Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology 259:329–345
   PubMed Web of Science ®Google Scholar
• Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. 2009. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. European Journal of Obstetrics, Gynecology, and Reproductive Biology 142:99–105.
   PubMed Web of Science ®Google Scholar
• Meyer-Siegler K, Fattor RA, Hudson PB. 1998. Expression of macrophage migration inhibitory factor in the human prostate. Diagnostic Molecular Pathology 7:44–50.
   PubMedGoogle Scholar
• Mitchell RA. 2004. Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cellular Signalling 16:13–19.
   PubMed Web of Science ®Google Scholar
• Mitchell RA, Bucala R. 2000. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Seminars in Cancer Biology 10:359–366.
   PubMed Web of Science ®Google Scholar
• Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, et al. 2001. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes and Development 15:968–980.
   PubMed Web of Science ®Google Scholar
• Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. 2002. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. American Journal of Epidemiology 155:217–224
   PubMed Web of Science ®Google Scholar
• Obermair A, Tempfer C, Hefler L, Preyer O, Kaider A, Zellinger R, et al. 1998. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. British Journal of Cancer 77:1870–1874.
   PubMed Web of Science ®Google Scholar
• Oehler MK, Caffier H. 1999. Diagnostic value of serum VEGF in women with ovarian tumors. Anticancer Research 19:2519–2522.
   PubMed Web of Science ®Google Scholar
• Paley PJ, Staskus KA, Gebhard K. 1997. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98–106
   PubMed Web of Science ®Google Scholar
• Repp AC, Mayhew ES, Apte S, Niederkorn JY. 2000. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. Journal of Immunology 165:710–715.
   PubMed Web of Science ®Google Scholar
• Robati M, Ghaderi A, Mehraban M, Shafizad A, Nasrolahi H, Mohammadianpanah M. 2013. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Archives of Gynecology and Obstetrics 288:859–865.
   PubMed Web of Science ®Google Scholar
• Schildkraut JM, Halabi S, Bastos E, Marchbanks PA, McDonald JA, Berchuck A. 2000. Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. Obstetrics and Gynecology 95:119–127.
   PubMed Web of Science ®Google Scholar
• Schutter EM, Kenemans P, Sohn C, Kristen P, Crombach G, Westermann R, et al. 1994. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 74:1398–1406.
   PubMed Web of Science ®Google Scholar
• Shi X, Leng L, Wang T, Wang W, Du X, Li J, et al. 2006. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25:595–606.
   PubMed Web of Science ®Google Scholar
• Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C. 1998. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstetrics and Gynecology 92:360–363.
   PubMed Web of Science ®Google Scholar
• Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. 2008. Diagnostic markers for early detection of ovarian cancer. Clinical Cancer Research 14:1065–1072.
   PubMed Web of Science ®Google Scholar
• Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, et al. 2005. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129:1485–1503.
   PubMed Web of Science ®Google Scholar
• Wu HM, Zhu SL, He LJ, Liu YH, Xie D. 2009. Clinical significance of macrophage migration inhibitory factor in invasion of ovarian cancer. Ai Zheng 28:1054–1060.
   PubMedGoogle Scholar
• Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, et al. 1997. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. British Journal of Cancer 76:1221–1227.
   PubMed Web of Science ®Google Scholar
• Zhang M, Lee AH, Binns CW. 2004. Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecologic Oncology 92:320–326.
   PubMed Web of Science ®Google Scholar